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Abstract
Glioblastoma multiforme (GBM) is the most common primary malignant adult brain tumor and is associated with poor
survival. Recently, stem-like cell populations have been identified in numerous malignancies including GBM. To identify
genes whose expression is changed with differentiation, we compared transcript profiles from a GBM oncosphere line
before and after differentiation. Bioinformatic analysis of the gene expression profiles identified podocalyxin-like protein
(PODXL), a protein highly expressed in human embryonic stem cells, as a potential marker of undifferentiated GBM stem-like
cells. The loss of PODXL expression upon differentiation of GBM stem-like cell lines was confirmed by quantitative real-time
PCR and flow cytometry. Analytical flow cytometry of numerous GBM oncosphere lines demonstrated PODXL expression in
all lines examined. Knockdown studies and flow cytometric cell sorting experiments demonstrated that PODXL is involved in
GBM stem-like cell proliferation and oncosphere formation. Compared to PODXL-negative cells, PODXL-positive cells had
increased expression of the progenitor/stem cell markers Musashi1, SOX2, and BMI1. Finally, PODXL expression directly
correlated with increasing glioma grade and was a marker for poor outcome in patients with GBM. In summary, we have
demonstrated that PODXL is expressed in GBM stem-like cells and is involved in cell proliferation and oncosphere formation.
Moreover, high PODXL expression correlates with increasing glioma grade and decreased overall survival in patients with
GBM.
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Introduction
Glioblastoma multiforme (GBM), World Health Organization
(WHO) grade IV astrocytoma, is the most common primary
malignant adult brain tumor and is treated with a combination of
surgery, radiation, and chemotherapy. These tumors remain
incurable with a current median survival of 14.6 months [1].
Stem-like cell populations have been identified in a number of
malignancies including GBM [2,3]. GBM stem-like cells are
heterogeneous populations that, like normal neural stem cells, are
self-renewing and multi-potent. These cells can differentiate along
both neuronal and glial lineages [2]. They grow as oncospheres in
vitro and, when implanted intracranially, form tumors histologically
identifiable as GBM [2]. Additionally, there is evidence these stem-
like cells are resistant to chemotherapy and radiotherapy [4,5].
Several methods have been proposed to isolate GBM stem-like
cells. One is the use of candidate stem cell markers, such as
CD133, CD15, CD44, integrin a6, and L1CAM, to isolate the
putative stem cell fraction from human GBMs [3,6–9]. There is,
however, a lack of consensus regarding these markers in the
literature. For example, isolation of the CD133-positive fraction
has been shown to miss cells with stem-like functions and several
studies have demonstrated that CD133-negative cells exhibit stem
cell capabilities [10–12]. Similarly, CD15 has literature both
supporting the claim of it being a GBM stem-like cell marker [6]
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and refuting that claim [13]. Although CD44 has been shown to
identify cancer stem cells in other pathologies [14], there is
controversy about this association with GBM stem-like cells [7,15].
The data on integrin a6 and L1CAM comes from populations first
identified by expression of CD133 [8,9]. These conflicting studies
reveal the difficulties involved in using stem cell markers.
Another method to identify these cells is based on the ‘‘side
population’’ of cells expressing ATP-binding cassette transporters,
which pump out Hoechst 33342 dye [16]. Other studies, however,
suggest a lack of specificity with this approach by demonstrating
toxicity of Hoechst dye which may have selected cells for their
resistance to this compound and not for their stem cell capabilities
per se [12]. An additional study demonstrated that side population
cells were unstable and could arise from non-side population cells
[17].
An alternate method to isolate GBM stem-like cells is to use
specific culturing conditions, including lack of serum and addition
of EGF and FGF-2 [2]. Lee et al. compared the genotypic and
phenotypic characteristics of such oncospheres to parental tumors
and related adherent GBM cell lines cultured in the presence of
serum and absence of EGF and FGF-2, derived from the same
parental tumors [18]. This study demonstrated a high degree of
similarity among the parental tumors, normal neural stem cell
lines, and cells cultured in EGF and FGF-2. The genotypes and
phenotypes of the adherent cells diverged significantly from the
parental tumors [18].
To identify genes whose expression is changed with oncosphere
differentiation, we compared transcript profiles of an undifferen-
tiated GBM stem-like cell line and its differentiated counterpart.
One of the genes significantly over-expressed in undifferentiated
stem-like cells was podocalyxin-like protein (PODXL). In this
study, we functionally characterize this protein in GBM stem-like
cells and investigate the clinical significance of expression of
PODXL in gliomas.
Materials and Methods
Cell lines
The GBM oncosphere lines 020913 (HSR-GBM1), HSR-
GBM2, HSR-GBM3, and 060919 have been previously described
[2,19,20]. The GBM oncosphere line TSC1228 was obtained
from Howard Fine at the National Institutes of Health and has
also been previously described [18]. Additional malignant glioma
oncosphere lines were established from fresh tumor tissue
immediately following resection at Johns Hopkins Hospital
(JHH), obtained under Johns Hopkins Medicine Office of Human
Subjects Research Institutional Review Board approval with
informed written consent. The cell lines were authenticated using
short tandem repeat profiling (data not shown). All lines were
maintained in NeuroCult medium (StemCell Technology, Van-
couver, BC, Canada) supplemented with 0.2% heparin (StemCell
Technology), hEGF (20 ng/mL, Peprotech, Rocky Hill, NJ), and
hFGF-2 (10 ng/mL, Peprotech). Differentiation was performed as
previously described [2].
RNA preparation
Total RNA was prepared with the RNAgents kit (Promega,
Madison, WI) following the manufacturer’s instructions. RNA
quality was assessed by denaturing agarose gel electrophoresis.
Serial analysis of gene expression (SAGE)
Micro long-SAGE was performed as previously described [21]
using 5–10 mg of total RNA isolated from 020913 cells that had
either remained undifferentiated or were fully differentiated
(incubated in differentiation medium for 28 days) [2]. The tags
from these SAGE libraries were then extracted using SAGE2000 v
4.5 software. The full sets of tag counts for these libraries are
available online [22,23].
Quantitative real-time PCR (qRT-PCR)
cDNAs from matched sets of undifferentiated and differentiated
GBM oncosphere lines were generated from total RNA using
Superscript II reverse transcriptase according to the manufactur-
er’s instructions (Invitrogen, Carlsbad, CA). qRT-PCR was
optimized and performed on a Bio-Rad iCycler machine (Bio-
Rad Laboratories, Hercules, CA) as previously described [24]
(primer sequences available upon request). At least two indepen-
dent qRT-PCR reactions were performed in triplicate. Expression
was normalized to COX6B, which was shown by SAGE to be at
roughly equivalent levels in both SAGE libraries, using iCycler
software version 3.0 (Bio-Rad Laboratories). For qRT-PCR of
Musashi1, SOX2, and BMI1, RNA was isolated from using Trizol
according to the manufacturer’s instructions (Invitrogen). cDNA
was synthesized using a QuantiTect Reverse Transcription kit
according to the manufacturer’s instructions (Qiagen, Valencia,
CA). qRT-PCR was performed as described above with minor
modifications. Expression was normalized to GAPDH (primer
sequences available upon request). At least two independent qRT-
PCR reactions were performed in quintuplicate. All qRT-PCR
products were resolved by electrophoresis on a 3% low-molecular
weight agarose/ethidium bromide gel to ensure a single product
was amplified.
Analytical flow cytometry
Oncospheres were triturated to obtain a single-cell suspension,
incubated with human and mouse pre-immune IgG (Sigma-
Aldrich, St. Louis, MO) for 15 minutes at room temperature,
stained with a phycoerythrin-conjugated mouse monoclonal anti-
PODXL (R&D Systems, Minneapolis, MN), a phycoerythrin-
conjugated mouse monoclonal anti-CD133/2 (Clone 293C,
Miltenyi Biotec, Auburn, CA) or a phycoerythrin-conjugated
isotype control mouse IgG2B or IgG2A antibody (Miltenyi Biotec,
R&D Systems; BD Biosciences, San Diego, CA) for 30 minutes on
ice, incubated with 7-amino-actinomycin D (7-AAD) (BD Biosci-
ences), and analyzed on a FACSCalibur (BD Biosciences).
Analytical flow cytometry was performed at least twice for each
oncosphere line. The percent positivity was determined by using a
gate set by 1.0% positive events from the isotype population.
Viral knockdown of PODXL
A MissionTM TRC-Hs (Human) clone set of five different
sequence-verified shRNA lentiviral plasmid vectors targeting
PODXL (TRCN0000117017 thru 21) was obtained from the
High Throughput Biology Center (Johns Hopkins University,
Baltimore, MD). A second set of five different sequence-verified
inducible shRNA lentiviral plasmid vectors (pTRIPZ) targeting
PODXL (V3THS_385278, V3THS_385276, V2THS_36329,
V2THS_36258, and V2THS_36259) was obtained to provide a
second shRNA construct (Thermo Scientific, Rockford, IL). The
lentiviruses were made as previously described [25]. Cells were
cultured for 5 to 7 days and then 10 mL of concentrated virus and
8 ng/mL of Polybrene (Sigma-Aldrich) were added. The medium
was changed after 24 hours. For the MissionTM TRC-Hs
plasmids, 0.5 mg/mL of puromycin (Sigma-Aldrich) were added
to the cultures three days after transduction. For the pTRIPZ
plasmids, 2 mg/mL doxycycline (Santa Cruz Biotechnology,
Dallas, TX) were added every 48 hours for plasmid induction,
both in the knockdown vector and the empty control vector.
PODXL in GBM
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Change in PODXL expression was determined by flow cytometry,
as described above, with minor modifications. For experiments
using pTRIPZ plasmids, an Alexa Fluor 488-conjugated mouse
monoclonal anti-PODXL antibody and an Alexa Fluor 488-
conjugated isotype control mouse IgG2A antibody (R&D Systems)
were utilized given the turboRFP (tRFP) expression associated
with induction of the plasmids. TRCN0000117018 and
V2THS_36258 shRNA sequences demonstrated the greatest
reduction of PODXL expression and were selected for further
knockdown studies.
Fluorescence-activated cell sorting (FACS)
The analysis and sorting were performed using Summit 4.3
software (DAKO USA, Carpinteria, CA) on a MoFlo MLS
(Beckman Coulter, Brea, CA) sorter equipped with a Coherent
Enterprise II 621 laser and a CyCLONE automated cloner. Two
primary GBM oncosphere lines, 020913 and JHU-0879, were
incubated with anti-PODXL antibody as described above. Gates
for the PODXL-positive and PODXL-negative cells were set using
an unstained population and an isotype-stained population. The
final gates were refined to the top and bottom 2.5–5% of cells
based on PODXL expression. In addition, the sorter was utilized
to count and plate cells for the proliferation and oncosphere
formation assays involving the lentiviral constructs. In the case of
the MissionTM TRC-Hs vectors, 7-AAD was utilized to gate on
live cells. For the pTRIPZ plasmids, tRFP expression was used to
gate on positively-transduced cells.
Cell proliferation assay
Proliferation was assessed using Alamar Blue (Invitrogen)
following the manufacturer’s instructions. Cells were counted
and plated at a concentration of 500 or 750 cells per 180 mL of
complete NeuroCult medium using the MoFlo MLS sorter as
described above, with 5 replicates at each concentration, in a 96-
well plate. The plates were read daily on a Victor3 automated plate
reader (Perkin Elmer, Waltham, MA). For lentiviral knockdown
and cell-sorting experiments, background fluorescence, deter-
mined by Alamar Blue in media alone, was subtracted from the
readings. For the pTRIPZ knockdown experiments, background
fluorescence was determined by adding 2 mg/mL doxycycline
every 48 hours to wells containing media and Alamar Blue. For
the MissionTM TRC-Hs plasmids, three independent transduc-
tions were performed. For the pTRIPZ plasmids, the proliferation
assay was performed in triplicate with independently induced
populations. For the PODXL-positive and PODXL-negative
sorted populations, two separate cell lines, 020913 and JHU-
0879, were used for three separate assays each.
Oncosphere formation/limiting dilution assay
Cell populations were obtained from lentiviral knockdown and
FACS. PODXL-positive or PODXL-negative cells were plated in
80 mL of complete NeuroCult medium in 96-well plates. PODXL-
positive cells were plated at concentrations of 1, 2, 5, 10, and 50
cells per well. PODXL-negative cells were plated at concentrations
of 1, 10, 50, 200, and 500 cells per well. For each concentration of
cells there were 48 wells. Plates were analyzed by light microscopy
for oncospheres, 12 to 20 days after plating. Positive wells were
defined as groups of cells larger than 125 mm in diameter.
Individual spheres from positive wells were triturated, re-plated,
and monitored for growth of new oncospheres. For the MissionTM
TRC-Hs plasmids, three independent transductions were per-
formed. For the pTRIPZ plasmids, the assay was performed in
triplicate with independently induced populations. For the
PODXL-sorted populations, the assay was run three times each
using two separate cell lines, 020913 and JHU-0879.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of GBMs (8 total
tumors) and tissue microarrays (TMAs) of WHO grades I–IV
astrocytomas with normal controls were stained as previously
described [26] using an anti-PODXL antibody (1:200, R&D
Systems) overnight at 4uC followed by incubation with a goat anti-
mouse IgG conjugated to horseradish peroxidase (Dako USA). A
total of 148 cases were represented in the TMAs, including 6
WHO grade I astrocytomas (pilocytic astrocytoma), 47 WHO
grade II diffuse astrocytomas, 41 WHO grade III anaplastic
astrocytomas, and 54 WHO grade IV GBMs. Three commercial
TMAs were used (US Biomax, Rockville, MD) and a fourth TMA
was generated at JHH (CGE). Each sample on the TMAs was
represented by one to three cores and staining intensity was
averaged across the replicate cores. Human kidney tissue served as
a positive control on the JHH TMA. Intensity of staining was
graded as negative, weak, or strong by a single neuropathologist
(CGE).
Tumor sample processing
Primary tumor samples were obtained and processed within
24 hours of resection. A total of 64 samples were processed: 2
grade I astrocytomas, 9 grade II diffuse astrocytomas, 10 grade III
anaplastic astrocytomas, and 43 grade IV GBMs. Samples were
mechanically dissociated using the two-scalpel method, a tissue
douncer, and passaging through a 16-gauge needle. The mixture
was then incubated with 10 mg/mL Collagenase IV (Invitrogen)
for 15 minutes at 37uC. After the mixture was passed through a
75 mm filter, the cells were incubated with a red blood cell lysis kit
(BD Biosciences) for 15 minutes at room temperature and washed
in filtered PBS +1% FBS. The resulting pellet was centrifuged in a
30% sucrose solution (w/v) at 3,000 g for 20 minutes. The cells
were resuspended in PBS and PODXL expression was analyzed
using analytical flow cytometry as described above.
Caspase assay
Apoptosis was assayed using the Caspase-Glo 3/7 Assay
(Promega) on JHU-0879 cells with MissionTM TRC-Hs knock-
down of PODXL following the manufacturer’s instructions,
incubating with Caspase-Glo for 1 hour at room temperature
prior to analysis. Each well contained 10,000 cells. As a positive
control, cells were treated with 20 mM of the multi-targeted
receptor tyrosine kinase inhibitor sunitinib (LC Laboratories,
Woburn, MA) at room temperature for three hours.
Survival Analysis
Kaplan-Meier Survival graphs and statistics were generated on
the Repository of Molecular Brain Neoplasia DaTa (RE-
MBRANDT) Database website, a joint initiative of the Neuro-
Oncology Branch of the National Cancer Institute and the
National Institute of Neurological Disorders and Stroke [23,27]. In
this database, PODXL expression was ascertained using Affyme-
trix GeneChipsH. Up-regulated expression was defined as a $26
increase in expression compared to non-tumor brain tissue.
Intermediate expression was defined as between a ,26 increase
and ,26decrease in expression compared to non-tumor samples.
Down-regulated expression was defined as a $26 decrease in
expression compared to non-tumor samples. The only sample in
which PODXL expression was down-regulated was excluded from
PODXL in GBM
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the final analysis. A total of 342 gliomas were analyzed, including
181 GBMs.
Statistical methods
The statistical significance of differentially expressed genes in
the SAGE libraries was assessed using Monte Carlo simulation.
RT-PCR data was analyzed using the 22DDCt method as
previously described [28]. P-values were calculated using a two-
sided, paired t-test of the absolute expression values. For analytical
flow cytometry of fresh tumor samples, results of PODXL
expression were analyzed using a Rank-sum test with a p-value
of ,0.05 (Stata version 11.1, College Station, Texas). For cell
proliferation assays, the linear portion of the resulting growth
curve was fit with a linear regression model and a two-sided t-test
was performed on the linear regression model (GraphPad, La
Jolla, CA). The limiting dilution assay was analyzed as described
previously [29] with statistical analysis done using Extreme
Limiting Dilution Analysis [30]. Immunohistochemistry results
were assessed by cross-tabulating PODXL positivity and tumor
grade using chi-square analysis (SAS, Cary, NC). The RE-
MBRANDT survival data were analyzed using a Kaplan-Meier
Survival graph and the effect of expression was modeled using
Cox-proportional hazard regression (Stata version 11.1).
Results
Gene expression profiling of undifferentiated and
differentiated GBM stem cells
To compare gene expression profiles of undifferentiated and
differentiated GBM stem-like cells, SAGE was performed on
undifferentiated and differentiated 020913 cells. Bioinformatic
analysis of the gene expression profiles of the undifferentiated and
differentiated cells identified numerous genes significantly over-
expressed in GBM oncospheres (Table 1, p,0.05); the genes over-
expressed in the differentiated GBM oncospheres are shown in
Table S1. PROMININ, the gene encoding the putative stem cell
marker CD133 [3], was modestly decreased from 16 to 12 tags
upon differentiation (data not shown), but was not statistically
significant at this level of tag sampling. Additionally, expected
increases in tag counts were observed for Tuj1 and GFAP upon
differentiation (data not shown), but did not reach statistical
significance. Most notably, PODXL, a gene expressed in human
embryonic stem cells (hESCs) [31–37], was highly over-expressed
in undifferentiated oncospheres. Further in silico analysis of
PODXL demonstrated high expression in both hESC and human
embryonal carcinoma cell lines (Figure S1).
To validate our SAGE results, we performed qRT-PCR of
several genes listed in Table 1 and Table S1 (DUSP6, PODXL,
PTPRZ1, FABP7, FAM70A, and MAN1C1) in the original line
utilized for the SAGE analysis as well as in two additional GBM
stem-like cell lines before and after differentiation. We confirmed
the change (loss or gain) of expression of these genes upon
differentiation. The only exception was FABP7, which exhibited
no change in expression upon differentiation in HSR-GBM3; in
the other lines, a loss of expression was observed (Table S2).
To confirm PODXL expression is altered with GBM stem-like
cell differentiation, we performed analytical flow cytometry for
PODXL on undifferentiated and differentiated cells from an
additional GBM stem-like cell line, JHU-0879. The cell surface
expression of PODXL was higher in undifferentiated cells
compared to differentiated cells, at 34.32% and 0.42%, respec-
tively (Figure S2A–B), confirming the SAGE and qRT-PCR
results. Analysis of CD133 was included as a control and its
expression was higher in undifferentiated cells compared to
differentiated cells, at 87.22% and 2.63%, respectively (Figure
S2C–D). Given the increased expression of PODXL in undiffer-
entiated GBM oncospheres and its high expression in hESC, we
chose to further characterize this protein in GBMs.
PODXL expression in GBM stem-like cells
We investigated the expression of PODXL in GBM oncosphere
lines by analytical flow cytometry on 3 previously established
(020913, 060919, and TSC1228) and numerous newly derived
GBM stem-like cell lines. All of the lines examined expressed some
degree of PODXL and the expression ranged from 42.6% to 93.1%
of the cell population (Figure 1). For subsequent functional studies,
we chose two GBM oncosphere lines, 020913 and JHU-0879.
PODXL is a marker of GBM stem-like cell proliferation
We next evaluated the functional role of PODXL in GBM
stem-like cell proliferation, utilizing both knockdown studies and
FACS. Initially, we evaluated five shRNA lentiviral vectors and
chose the one with the strongest reduction of PODXL expression,
TRCN0000117018 (Figure 2A and D). JHU-0879 cells were then
transduced with either the PODXL knockdown lentivirus or an
empty control lentivirus. The control cells grew significantly faster
than the PODXL knockdown cells (p,0.0001, Figure 2B–C).
To confirm the results were due to the knockdown of PODXL
and not off-target effects of the lentiviral insertion, a second
shRNA screen was performed with a panel of inducible
lentiviruses. Selecting the sequence with the strongest reduction
of PODXL expression, V2THS_36258 (Figure 2A), proliferation
assays were again performed in comparison to an empty control
lentivirus. The control cells grew significantly faster than the
PODXL knockdown cells (p = 0.0092, Figure 2E–F).
We then examined the role of PODXL in GBM stem-like cell
proliferation by using FACS. Two independent GBM oncosphere
lines, 020913 and JHU-0879, were sorted for the presence or
absence of PODXL (Figure 3A, D). In each case, sort purity
exceeded 95%. For each cell line, the PODXL-positive population
of cells had a significantly faster growth rate compared to the
PODXL-negative population (p,0.0001, Figure 3B–C, E-F).
Taken together, these results demonstrate that PODXL is involved
in proliferation of GBM stem-like cell lines.
PODXL expression is associated with oncosphere
formation
We next investigated the role of PODXL in oncosphere
formation. Our initial studies compared cells transduced with
the control lentivirus to cells transduced with the PODXL-
knockdown shRNA lentivirus TRCN0000117018 in JHU-0879.
The percent of wells without oncospheres was graphed against the
concentration of cells. In the PODXL-positive population, 1:64
cells (1.56%) were oncosphere initiating cells whereas in the
PODXL-negative population, 1:374 cells (0.27%) were onco-
sphere initiating cells (p,0.0001, Figure 4A). Similar results were
obtained with the inducible lentivirus, V2THS_36258, which
demonstrated 1:38 cells (2.63%) were oncosphere initiating cells in
the PODXL-positive population compared to 1:125 cells (0.80%)
in the PODXL-negative population (p,0.0001, Figure 4B).
We next carried out this experiment with sorted PODXL-
positive and PODXL-negative populations in both 020913 and
JHU-0879 (Figure 4D and E). In 029013, this assay revealed that
for the PODXL-positive population, 1:37 cells (2.70%) were
oncosphere initiating cells while in the PODXL-negative popula-
tion, 1:632 cells (0.16%) were oncosphere initiating cells
(p,0.0001). This showed a greater than 10-fold enrichment in
PODXL in GBM
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the PODXL-positive population with oncosphere-initiating cells
(Figure 4D). In JHU-0879, 1:53 cells (1.89%) in the PODXL-
positive population were oncosphere initiating cells while 1:356
cells (0.28%) in the PODXL-negative population were oncosphere
initiating cells. Spheres from positive wells were replated as
individual cells and were able to form new oncospheres and could
be differentiated into multiple lineages (data not shown). Taken
together, these studies demonstrate that PODXL expression
correlates with oncosphere formation.
PODXL expression correlates with other stem cell
markers
We next chose to investigate the expression of the progenitor/
stem cell markers, Musashi1, SOX2 and BMI1. JHU-0879 cells
were transduced with either an empty control vector or a
PODXL-knockdown vector and these genes analyzed by qRT-
PCR. Expression of Musashi1, SOX2, and BMI1 was increased
1.7-, 1.3-, and 2.0-fold, respectively, compared to control cells
(Figure 4C, p= 0.003, = 0.303, and = 0.0058, respectively). To
validate these findings, similar analysis was performed with
020913 cells sorted into PODXL-positive and PODXL-negative
populations. Expression of Musashi1, SOX2, and BMI-1 was
increased 3.4-, 2.4-, and 4-fold, respectively, in the PODXL-
position population (Figure 4F, p,0.0001, = 0.0015, and =
0.0002, respectively). JHU-0879 was also sorted into PODXL
positive and negative populations and demonstrated similar
changes in these genes (data not shown). These data demonstrate
Table 1. Table of genes up-regulated greater than 8 fold in undifferentiated GBM oncospheres.
SAGE tag sequence UniGene ID Gene symbol (name) Fold incr doublets
GGTACCCATT Hs.298654 DUSP6 (dual specificity phosphatase 6) 19.39
GATTTGCCCT Hs.652175 TRIB2 (tribbles homolog 2) 16.33
TTTTATAATT Hs.26770 FABP7 (fatty acid binding protein 7) 13.27
TATATTGTAC Hs.18676 SPRY2 (sprouty homolog 2) 12.25
AATGACTGAA Hs.93659 PDIA4 (protein disulfide isomerase family A, member 4) 11.23
GACGCCCTGC Hs.56663 OLIG1 (oligodendrocyte transcription factor 1) 11.22
GACCCTGGGG Hs.467151 JOSD2 (josephin domain containing 2) 11.22
CTCAGCAAAC Hs.404056 EIF3S1 (eukaryotic translation initiation factor 3, subunit 1
alpha, 35 kDa)
10.2
TGGAAGGACC Hs.5086 MGC10433 10.2
GAGTTTGTCC Hs.438877 NLGN3 (neuroligin 3) 10.2
GTCAGAACTT Hs.602085 PHLDA1 (pleckstrin homology-like domain, family A,
member 1)
9.18
TCAAATGCAA Hs.584842 SART3 (squamous cell carcinoma antigen recognized by
T cells 3)
9.18
CTACCCTTTC Hs.363137 TCP1 (t-complex 1) 9.18
ATGCTGCCAA Hs.304792 PROSC (proline synthetase co-transcribed homolog
[bacterial])
9.18
GAGGACACAG Hs.16426 PODXL (podocalyxin-like) 8.16
ATAATTGACT Hs.15591 COPS6 (COP9 constitutive photomorphogenic homolog
subunit 6 [Arabidopsis])
8.16
GAATTACAGT Hs.653288 RNF12 (ring finger protein 12) 8.16
GAACCTTGAG Hs.591140 FOXK2 (forkhead box K2) 8.16
GTCTGAGCTC Hs.66915 C22orf16 8.16
GCCAGACACC Hs.525232 LRP10 (low density lipoprotein receptor-related
protein 10)
8.16
TTCACTGCCG Hs.78089 ATP6V1F (ATPase, H+ transporting, lysosomal 14 kDa, V1
subunit F)
8.16
TACCTTCCTT Hs.592164 POFUT2 (protein O-fucosyltransferase 2) 8.16
AGCTATTCCT AAGAACATTG Hs.368404 Hs.387567 EXT2 (exostoses [multiple] 2) ACLY (ATP citrate lyase) 8.16 8.16
CAAGAAAGCA Hs.422181 S100B (S100 calcium binding protein B) 8.16
CGCTTTGCGC Hs.529782 VCP (valosin-containing protein) 8.16
TGTCCCCTCA Hs.525622 AKT1 (v-Akt murine thymoma viral oncogene homolog 1) 8.16
GTACTAGTGT Hs.303649 CCL2 (chemokine [C-C motif] ligand 2) 8.16
ATACTGCTGC Hs.82919 CUL2 (cullin 2) 8.16
TATTTTTTTA Hs.533122 SFRS10 (splicing factor, arginine/serine-rich 10
[transformer 2 homolog, Drosophila])
8.16
TGACTAATAA Hs.77867 ADORA1 (adenosine A1 receptor) 8.16
doi:10.1371/journal.pone.0075945.t001
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that cells expressing PODXL contain markers of early progenitor/
stem cells.
Clinical implications of PODXL expression in human
gliomas
We next chose to examine expression of PODXL in GBM tissue
samples. Initially, eight independent GBM samples were evaluated
for PODXL by immunohistochemistry. Of these eight specimens,
one was negative for PODXL (Figure 5A), four showed weak
PODXL staining (Figure 5B), and three showed strong PODXL
staining (Figure 5C). Of the samples positive for PODXL, staining
was diffuse throughout the tumor. Interestingly, in several samples,
PODXL was differentially expressed in the tumor and PODXL
staining was highest in the perivascular regions (Figure 5D) as well
as in the pseudopalisading cells surrounding the necrotic areas
(Figure 5E). PODXL immunoreactivity was present within
necrotic foci, which may represent an artifact, but positively
stained viable cells were also found in the pseudopalisading regions
around the necrotic areas and also further away from regions of
cell death. Endothelial cells within the tumor showed moderate to
strong staining.
To further investigate the expression of PODXL in human
gliomas, we examined the relationship between PODXL expres-
sion and tumor grade by performing immunohistochemistry on
TMAs containing a total of 148 gliomas. We observed varying
degrees of cytoplasmic and cell membrane staining (Figure 6A).
Figure 1. Analytical flow cytometry of GBM oncosphere lines for PODXL. All GBM oncosphere cell lines tested expressed PODXL, with the
majority of the cell lines showing moderate expression of PODXL. The numbers represent the percent of cells positive for PODXL. The gate was set
using 1.0% positive events from the PE-isotype population. The percent positive ranged from 42.6% to 93.1%.
doi:10.1371/journal.pone.0075945.g001
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Higher grade tumors had higher levels of immunoreactivity and
there was a statistically significant association between PODXL
expression and glioma grade (p,0.0001, Figure 6B–C).
We next examined the relationship of PODXL expression with
astrocytoma grade on a total of 64 freshly resected gliomas. Tumor
specimens were obtained directly from the operating room and
analyzed, using flow cytometry, for the expression of PODXL.
Using a Rank-sum test, we determined that there was a statistically
significant difference in expression between grade II astrocytomas
and GBMs (p = 0.001), and between grade II astrocytomas and
grade III anaplastic astrocytomas (p= 0.047) (Figure 7). Taken
together, these findings demonstrate that PODXL is expressed in
primary human GBMs and that its expression level correlates
positively with glioma grade.
We next examined the relationship between PODXL gene
expression and patient outcome using the REMBRANDT data set
Figure 2. Knockdown of PODXL expression correlates with decreased cell proliferation. (A): Lentiviral knockdown of PODXL expression, as
assayed by flow cytometry, using the two shRNA sequences utilized for functional studies. (B): Representative growth curve of PODXL knockdown
with TRCN0000117018 and control knockdown in JHU-0879 cells over 7 days and (C) the linear regression fit of the growth curves (p,0.0001).
Quantitatively similar results were obtained with each replicate. (D): Analytical flow cytometry histogram of JHU-0879 cells transduced with either
control virus (red) or TRCN0000117018 virus (blue), demonstrating the knockdown of PODXL expression. (E): Representative growth curve of PODXL
knockdown with V2THS_36258 and control knockdown in JHU-0879 cells over 7 days and (F) the linear regression fit of the growth curves
(p = 0.0092). Quantitatively similar results were obtained with each replicate.
doi:10.1371/journal.pone.0075945.g002
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Figure 3. PODXL expression correlates with cell proliferation. (A): Representative post-sort analytical flow for PODXL-positive (blue) and
PODXL-negative (green) populations in 020913 cells showing minimal overlap between the two populations. (B): Representative growth curves of the
PODXL-positive and PODXL-negative populations from 020913 over 7 days and (C) the linear regression fit of the growth curve through day 7
(p,0.0001). Quantitatively similar results were obtained with each replicate. (D): Histogram of JHU-0879 FACS showing the gated PODXL-positive
(blue) and PODXL-negative (green) populations. (E): Representative growth curves of the PODXL-positive and PODXL-negative populations from JHU-
0879 over 7 days and (F) the linear regression fit of the growth curve through day 7 (p,0.0001). Quantitatively similar results were obtained with
each replicate.
doi:10.1371/journal.pone.0075945.g003
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Figure 4. PODXL expression correlates with oncosphere formation. (A): Results of the limiting dilution assay using PODXL knockdown with
TRCN0000117018 compared to control virus in JHU-0879. The 0.37 intercept was 64 cells/well for the control cells and 374 cells/well for the PODXL
knockdown cells. Inset shows a control well, left, and a PODXL knockdown well, right (406). Quantitatively similar results were obtained with two
additional knockdown experiments. (B): Results of the limiting dilution assay using PODXL knockdown with V2THS_36258 compared to control virus
PODXL in GBM
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[27]. PODXL expression was up-regulated in 85 gliomas and
expressed at an intermediate level in 257 gliomas (Table S3).
Patients with gliomas and up-regulated PODXL expression had a
significantly shorter overall survival than those with intermediate
PODXL expression (p,0.0001) (Figure 8A). The median overall
survival of patients with up-regulated PODXL expression was 12
months, compared to a median overall survival of 22 months in
patients with intermediate PODXL expression (Hazard ratio of
1.92, p,0.0001) (Figure 8B). This analysis contains patients with
all glioma grades; we next evaluated only patients with GBM.
GBM patients with up-regulated PODXL expression had a
significantly shorter overall survival than patients with intermedi-
ate expression (p = 0.0003) (Figure 8C). The median overall
survival of patients with up-regulated PODXL expression was 11
months, compared to a median overall survival of 17 months in
patients with intermediate PODXL expression (Hazard ratio of
1.67, p = 0.001) (Figure 8D). Taken together, these studies
demonstrate that PODXL expression is correlated with glioma
grade and that PODXL is a marker for overall worse survival in
patients with GBMs.
Discussion
In this study, we performed transcript profiling of a GBM
oncosphere line before and after differentiation. One of the
notable genes up-regulated in the undifferentiated oncospheres
was PODXL. As this gene is highly expressed in hESC [31–37]
and other human malignancies [38–54], this was the focus of the
current studies. Our findings demonstrate that PODXL is involved
in GBM stem-like cell proliferation and oncosphere formation and
that high PODXL expression correlates with glioma grade and
decreased overall survival in patients with GBMs.
PODXL is a cell surface glycoprotein which is closely related to
CD34 and endoglycan. It is physiologically expressed by kidney
podocytes, hematopoietic progenitors, and vascular endothelia
[47]. This protein was first identified as a 140 kDa cell surface
protein on renal glomerular epithelial cells [55]; Podxl2/2 mice
died of anuric renal failure within 24 hours of birth due to lack of
in JHU-0879. The 0.37 intercept was 38 cells/well for the control cells and 125 cells/well for the PODXL knockdown cells. Quantitatively similar results
were obtained with two additional knockdown experiments. (C): qRT-PCR results of Musashi1, SOX2, and BMI1 gene expression in JHU-0879 cells
transduced with either PODXL shRNA or control virus. Expression was normalized to GAPDH expression. ns: p.0.05; *: p#0.01. (D): Results of the
limiting dilution assay using PODXL-positive cells compared to PODXL-negative cells obtained using FACS on 020913. The 0.37 intercept was 37 cells/
well for the PODXL-positive cells and 632 cells/well for the PODXL-negative cells. Inset shows a PODXL-positive well, left, and a PODXL-negative well,
right (406). Quantitatively similar results were obtained with two additional FACS experiments using 020913. (E): Results of the limiting dilution assay
using PODXL-positive cells compared to PODXL-negative cells obtained using FACS on JHU-0879. The 0.37 intercept was 53 cells/well for the PODXL-
positive cells and 356 cells/well for the PODXL-negative cells. Quantitatively similar results were obtained with two additional FACS experiments
using JHU-0879. (F): qRT-PCR results of Musashi1, SOX2, and BMI1 gene expression comparing FACS-sorted PODXL-positive and PODXL-negative
populations from 020913. Expression was normalized to GAPDH expression. *: p#0.01; **: p#0.001.
doi:10.1371/journal.pone.0075945.g004
Figure 5. Immunohistochemical staining for PODXL expression in GBMs. Immunohistochemical staining for PODXL revealed (A) negative,
(B) weak, or (C) strong levels of expression of PODXL. (C): Inset demonstrates positive staining in viable peri-necrotic cells. Tumor cells in (D)
perivascular regions and (E) around necrotic foci often contained higher levels of PODXL expression. (F): Renal glomeruli served as a positive control
(A–E scale bar = 50 mm, C inset scale bar = 12 mm, F scale bar = 25 mm).
doi:10.1371/journal.pone.0075945.g005
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filtration slits between renal glomeruli foot processes and
formation of tight junctions between adjacent podocytes [56].
Subsequent studies have demonstrated that PODXL plays a role
in cell adhesion [47,56–59].
Our SAGE analysis, qRT-PCR, and flow cytometric results
demonstrated that PODXL is overexpressed in undifferentiated
oncospheres compared to their differentiated progeny. Further-
more, bioinformatic analysis of SAGE transcript profiles [23]
revealed that PODXL was highly expressed in hESCs. This is
consistent with several previous studies which have demonstrated
high expression of PODXL in hESCs [31–37] and that PODXL
expression is lost as cells began to differentiate [32,35]. The
association of PODXL with hESCs is significant, as a recent paper
demonstrated preferential overexpression of hESC markers in
poorly differentiated cancers, including GBM [60].
PODXL has also been found in adult stem cell populations.
PODXL has been shown to be a marker for early progenitor cells
for multipotent mesenchymal stromal cells (MSCs) [61]. Addi-
tional studies have identified PODXL on human and murine
progenitor hematopoietic stem cells, but not on mature blood cells
[34,43]. These reports further support a role for PODXL in stem
cell populations.
With respect to the brain, PODXL has been found in
developing and adult brain. PODXL expression was highest in
the postnatal murine cerebellum, cortical plate, and hippocampus
[62], the latter containing a niche for neural stem cells. Functional
analysis of PODXL in normal mouse brain showed loss of
Figure 6. Immunohistochemical analysis of PODXL expression in gliomas. (A): Immunohistochemical staining for PODXL revealed negative
(left column), weak (middle column), or strong (right column) levels of expression of PODXL (upper row 406 magnification, lower row 2006
magnification). (B): Graphical representation of PODXL expression in tumor cells versus glioma grade. Red lines indicate median immunopositivity. (C):
Table of PODXL immunopositivity versus grade of astrocytoma.
doi:10.1371/journal.pone.0075945.g006
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PODXL resulted in increased ventricular size and intraventricular
capillary formation [63] as well as decreased axonal elongation,
branching, and synaptogenesis [64]. PODXL was shown to be
expressed in migrating cells in the developing cerebellum and
proposed to participate in neuronal migration and detachment of
migrating neurons from radial glia [65].
Taken together, these previous studies support a role for PODXL
as a marker for hESC, MSCs, progenitor hematopoietic stem cells,
and developing brain tissue. Our data, which demonstrate that
PODXL is a marker of undifferentiated GBM stem-like cells, are
consistent with these findings. A recent study using lectin
microarrays found six glycoproteins, including PODXL, to be
differentially expressed between the stem-like oncosphere line
020913 and the traditional adherent line U373 [15].
We examined the function of PODXL in GBM stem-like cells
and demonstrated that PODXL is involved in proliferation. Both
viral knockdown studies and cell sorting experiments showed that
PODXL positive cells grow significantly faster than PODXL
negative cells. We did notice a smaller difference in growth rates
between V2THS_36258 PODXL knockdown and its control virus
than between TRCN0000117018 and its control virus. We feel
this is most likely due the decreased level of PODXL knockdown
achieved with V2THS_36258, as shown in Figure 2A. To the best
of our knowledge, this is the first demonstration of a direct
functional role of PODXL in cell proliferation.
In addition to establishing a role in GBM stem-like cell
proliferation, our results demonstrated that PODXL is involved in
oncosphere formation. Both viral knockdown assays and cell
sorting experiments demonstrated that PODXL positive cells are
able to form oncospheres in a limiting dilution assay. The
determined concentration of PODXL-positive cells required to
form an oncosphere was significantly lower than that of the
PODXL-negative cells, demonstrating that the PODXL-positive
population contains more cells capable of clonal replication.
Although the mechanism(s) remains to be established, this does not
appear to involve apoptosis as PODXL shRNA knockdown studies
and FACS analysis show no statistical difference in caspase activity
between these two populations (Figure S3).
The role of PODXL as a marker for undifferentiated GBM stem-
like cells is further supported by the increased expression of the early
progenitor/stem cell markers Musashi1, SOX2, and BMI1 in
PODXL positive cells [66]. We evaluated the expression levels of
these markers and found them to be increased in the PODXL-
positive cells compared to the PODXL-negative cells. Taken
together, these results demonstrate that PODXL is involved in
GBM stem-like cell proliferation, oncosphere formation, and marks
cells with increased early progenitor/stem cell marker expression.
We additionally examined the expression of PODXL in gliomas
and demonstrated that PODXL is overexpressed in the majority of
GBMs and that PODXL expression is correlated with tumor
grade, demonstrated in both fixed specimens and fresh tissue. This
is consistent with previous findings of PODXL over-expression in
a variety of other cancers, including leukemias [42,43], pancreatic
ductal adenocarcinoma [46], invasive breast carcinomas [50],
prostate cancer [67], Wilms tumor [51], hepatocellular carcinoma
[40], embryonal carcinoma (EC) [48,49], small cell lung carcino-
ma (SCLC) [44], undifferentiated thyroid carcinomas [52],
colorectal cancers [45], renal cell carcinoma [41], endometrial
adenocarcinoma [53], ovarian carcinomas [54], and GBM [39].
Mutations affecting the extracellular domain of PODXL are
associated with an increased risk of prostate cancer and
development of a more aggressive prostate cancer [38]. Overex-
pression of PODXL has been reported to correlate with a more
aggressive phenotype of breast cancer [67], prostate cancer [67],
and renal cell carcinoma [41]. A number of other studies have
demonstrated an inverse correlation between PODXL expression
and degree of tumor differentiation. This has been observed in
breast cancers [50], GBMs [39], and thyroid cancers [52].
PODXL has also been shown to be expressed in several cancers
with stem-like cell populations [44,48]. In EC, PODXL was
shown to be a marker of undifferentiated EC cells when compared
with EC cells forced to differentiate by retinoic acid [48].
Additionally, in SCLC, PODXL was found to be co-expressed
with BMI1 in multipotent precursor cells [44].
Our analysis, utilizing the REMBRANDT data set, demon-
strated that up-regulation of PODXL predicts worse survival for
patients with glioma. Of even greater significance is that, within
the GBM cohort alone, tumors with up-regulated PODXL
expression were associated with a significantly shorter overall
survival. One important consideration in this analysis is the lack of
specificity of cell type in the REMBRANDT data set. Our data
and the work of others [68] demonstrate that PODXL is expressed
in endothelium. As such, the REMBRANDT data reflects
PODXL staining in both tumor cells and also the associated
vasculature in the sample. Although this is a potential confounding
variable, the amount of PODXL expressed in vessels in our
immunohistochemical studies (Figures 5 and 6) was a minor
Figure 7. Correlation of level of PODXL expression with tumor
grade. Cells were obtained from fresh tumor tissue samples and
analyzed by flow cytometry for the fraction of PODXL expressing cells.
There is a statistically significant difference in expression between
Grade II astrocytomas and GBMs (Rank-sum test, p = 0.001), and
between Grade II astrocytomas and Grade III anaplastic astrocytomas
(Rank-sum test, p = 0.047).
doi:10.1371/journal.pone.0075945.g007
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component and thus we feel the survival curves are primarily
reflective of expression in the tumors cells.
In addition to PODXL’s involvement in cell adhesion, it has
been demonstrated to play a role in invasion. PODXL has been
shown to increase the invasive and migratory potential of MCF7
breast cancer and PC3 prostate cancer cells in vitro and leads to an
increase in mitogen-activated protein kinase and phosphatidylino-
sitol 3-kinase activity [67]. During review of this manuscript, an
additional study investigating the role of PODXL in glioma cell
invasion was published, demonstrating that expression of PODXL
increases in vitro invasion and protects against chemotherapeutic
activity [69]. Additional studies will be necessary to further explore
the role of PODXL in glioma invasion.
Conclusion
In this study, we demonstrate PODXL is expressed in
undifferentiated GBM stem-like cells. PODXL expression corre-
lates with cellular proliferation and oncosphere formation and
PODXL-positive cells express higher levels of stem cell markers
compared to their PODXL-negative counterparts. Finally, high
PODXL expression correlates with glioma grade and poorer
outcome in patients with GBM.
Supporting Information
Figure S1 SAGE Genie bioinformatic analysis of
PODXL expression. Bioinformatic analyses of transcript
expression data revealed that PODXL is highly expressed in
human embryonic stem cell lines as well as human embryonal
carcinoma cell lines (http://cgap.nci.nih.gov/SAGE).
(TIF)
Figure S2 Analytical flow cytometry of PODXL and
CD133 expression in undifferentiated and differentiated
JHU-0879 cells. Expression of both PODXL and CD133
decrease upon differentiation. (A): JHU-0879 cells stained with
PE-PODXL antibody and PE-isotype antibody, demonstrating
22.51% positivity. (B): Differentiated JHU-0879 cells stained with
PE-PODXL antibody and PE-isotype antibody, demonstrating
0.42% positivity. (C): JHU-0879 cells stained with PE-CD133
antibody and PE-isotype antibody, demonstrating 87.22% positiv-
ity. (D): Differentiated JHU-0879 cells stained with PE-CD133
antibody and PE-isotype antibody, demonstrating 2.63% positivity.
(TIF)
Figure S3 PODXL knockdown does not induce apoptosis.
GBM stem-like cell line JHU-0879 was transduced with either
shControl or shPODXL and assayed for Caspase 3/7 activity. The
positive control was sunitinib at 20 mM and the negative control
was wells without cells. There was no apoptosis seen with PODXL
knockdown.
(TIF)
Table S1 Genes overexpressed in differentiated GBM
oncospheres.
(DOCX)
Figure 8. Analysis of REMBRANDT data. (A): Kaplan-Meier survival curves showing overall survival of glioma patients with high PODXL
expression is shorter than glioma patients with intermediate PODXL expression (p,0.0001). (B): Median survival in months and hazard ratios of up-
regulated expression of PODXL compared to intermediate expression of PODXL in all glioma patients. (C): Kaplan-Meier survival curve for GBM
patients only, showing overall survival of patients with high PODXL expression is shorter than that of patients with intermediate PODXL expression
(p = 0.001). (D): Median survival in months and hazard ratios of up-regulated expression of PODXL compared to intermediate expression of PODXL in
GBM patients only.
doi:10.1371/journal.pone.0075945.g008
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Table S2 Quantitative real-time PCR expression anal-
ysis in three matched sets of undifferentiated and
differentiated GBM oncosphere lines.
(DOCX)
Table S3 Pathological diagnoses of the REMBRANDT
dataset.
(DOCX)
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